EUVIMEDEUVIMED entdecken
Crossref

Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients

Irene Assaf, Giacomo Bregni, Geraldine Anthoine, Thomas Aparicio, Pascal Artru, Meher Ben Abdelghani, Marc Buyse, Benoist Chibaudel, Elisabeth Coart, Marie Diaz, Camille Evrard, Karen Geboes und 7 weitere

Clinical Colorectal Cancer · 2025

DOI: 10.1016/j.clcc.2024.08.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2025. Verfasst von Irene Assaf und 18 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Oncologie Digestive, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgiu…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Circulating Tumor DNA, Colorectal Neoplasms. Die Arbeit nennt 17 Literaturangaben. Gefördert von: Roche, Foundation Medicine Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Evidence suggests that ctDNA may be a reliable biomarker to monitor metastatic colorectal cancer (CRC) evolution. Nevertheless, evidence on the potential of liquid biopsy in this setting is still low quality, mostly consisting of retrospective studies. METHODS: COPERNIC is an international, multicenter clinical trial. The pilot study aims to confirm the predictive potential of early on-treatment ctDNA dynamics, and inform the design of a larger ctDNA-driven trial. Advanced CRC patients who are candidates for ≥3rd lines of systemic therapy undergo longitudinal blood sample collection during treatment (day 1, 15 and 29 for 2- or 4-weekly treatment regimens; day 1, 22 and 43 for 3-weekly treatment regimens) and at each imaging assessment. ctDNA analyses are carried out with the FoundationOne Liquid CDx and FoundationOneMonitor assays, and ctDNA changes during treatment are correlated with radiologic response (as assessed every 8-12 weeks by RECIST v1.1). The primary objective is to select the optimal timepoint and cut-off value for early ctDNA changes (at day 15/22) to predict progressive disease as best radiological response with a high positive predictive value. The cut-off value for ctDNA will be defined based on nonparametric ROC-curves with bootstrapping. Based on the expected rate of progressive disease and statistical assumptions, 109 patients are needed to be screened to have 87 assessable patients. COPERNIC is sponsored by the Institut Jules Bordet, and supported by Roche and Foundation Medicine. Recruitment is open in 13 centres across Belgium and France. The study is registered with clinicaltrials.gov (NCT05487248).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCirculating Tumor DNAColorectal NeoplasmsHumansDisease ProgressionDrug Resistance, NeoplasmLiquid BiopsyMulticenter Studies as TopicPilot ProjectsClinical Trials as Topic

Stichwörter der Autor:innen

Circulating tumour DNAEarly treatment switchEarly tumour response assessment

Substanzen

Biomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Service d'Oncologie Digestive, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium.
  • Service de Gastroentérologie et Cancérologie Digestive, Hôpital Saint Louis, Paris, France.
  • Service de Gastroentérologie et Oncologie Digestive, Hôpital Privé Jean Mermoz, Lyon, France.
  • Service d'Oncologie Médicale, Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg, France.
  • International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.
  • Service d'Oncologie Médicale, Hôpital Franco Britannique - Fondation Cognacq-Jay, Cancérologie Paris Ouest, Levallois-Perret, France.

Förderung

  • Roche
  • Foundation Medicine Inc

Zitieren

APA

Assaf, I., Bregni, G., Anthoine, G., Aparicio, T., Artru, P., Abdelghani, M. B., Buyse, M., Chibaudel, B., Coart, E., Diaz, M., Evrard, C., Geboes, K., Ghiringhelli, F., Puleo, F., Raimbourg, J., Vandamme, T., Van den Eynde, M., Hendlisz, A., & Sclafani, F. (2025). Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.08.004

Vancouver

Assaf I, Bregni G, Anthoine G, Aparicio T, Artru P, Abdelghani MB, et al. Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients. Clinical Colorectal Cancer. 2025. doi:10.1016/j.clcc.2024.08.004

BibTeX
@article{Assaf2025,
  author = {Assaf, Irene and Bregni, Giacomo and Anthoine, Geraldine and Aparicio, Thomas and Artru, Pascal and Abdelghani, Meher Ben and Buyse, Marc and Chibaudel, Benoist and Coart, Elisabeth and Diaz, Marie and Evrard, Camille and Geboes, Karen and Ghiringhelli, François and Puleo, Francesco and Raimbourg, Judith and Vandamme, Timon and Van den Eynde, Marc and Hendlisz, Alain and Sclafani, Francesco},
  title = {Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients},
  journal = {Clinical Colorectal Cancer},
  year = {2025},
  doi = {10.1016/j.clcc.2024.08.004}
}
Kostenlos starten →